Board of Directors

Daniel J. Levangie: Chairman of the Board
John K. Bakewell: Director
Jeffrey B. Child: Director
Richard B. Emmitt: Director
Douglas W. Kohrs: Director
John L. Miclot: Director
Robert J. Palmisano: Director
Thomas E. Timbie: Director
Elizabeth H. Weatherman: Director

Executive Officers

Robert J. Palmisano: President and Chief Executive Officer
Pascal E.R. Girin: Executive Vice President and Chief Operating Officer
Shawn McCormick: Senior Vice President, Chief Financial Officer
Stacy Enxing Seng: Executive Vice President and President, Worldwide Peripheral Vascular
Kevin M. Klemz: Senior Vice President, Secretary and Chief Legal Officer
Christine R. Kowalski: Senior Vice President, Operations
Gregory Morrison: Senior Vice President, Human Resources
David H. Mowry: Senior Vice President and President, Worldwide Neurovascular
Julie D. Tracy: Senior Vice President, Chief Communications Officer
Brett A. Wall: Senior Vice President and President, International

Corporate Information

ev3 Corporate World Headquarters: ev3 Inc.; 3033 Campus Drive; Plymouth, MN 55441; USA; 763.398.7000
Peripheral Vascular Division: ev3 Endovascular, Inc.; 3033 Campus Drive; Plymouth, Minnesota 55441; USA; 763.398.7000
Neurovascular Division: ev3 Neurovascular; 9775 Toledo Way; Irvine, CA 92618; USA; 949.837.3700
ev3 Europe/International Headquarters: ev3 Europe SAS; 106-108 rue La Boétie; 75008 Paris; France; +33 156.88.59.10
Corporate Counsel: Oppenheimer Wolff & Donnelly LLP; Minneapolis, MN
Independent Registered Public Accounting Firm: Ernst & Young LLP; Minneapolis, MN
Transfer Agent: Wells Fargo Shareowner Services; 161 North Concord Exchange; South St. Paul, MN 55075; 651.450.4000
Investor Relations: ev3 Inc.; 3033 Campus Drive; Plymouth, MN 55441; 949.680.1375
Stock Listing: ev3 is traded on the NASDAQ Global Select Market under EVVV.
Annual Meeting: May 25, 2010; 2:00 p.m. (CDT); ev3 Inc.; 3033 Campus Drive; Plymouth, MN 55441; 763.398.7000

Statements contained in this report that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by words such as “expect,” “anticipate,” “plan,” “will,” “may,” “believe,” “continue,” or other words of similar meaning. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause our actual results to be materially different than those expressed in or implied by our forward-looking statements. Such uncertainties and risks include, among others, our future operating results and financial performance, fluctuations in foreign currency exchange rates, the effect of the global economic crisis, the timing of regulatory approvals and introduction of new products, market acceptance of new products, success of clinical testing, availability of third party reimbursement, impact of competitive products and pricing and effect of regulatory actions. More detailed information on these and other factors that could adversely affect our business and operating results are described in Form 10-K.